Olympic Medical Center | |
939 Caroline St, Port Angeles, Washington 98362 | |
(360) 417-7000 | |
Name | Olympic Medical Center |
---|---|
Type | Acute Care Hospital |
Location | 939 Caroline St, Port Angeles, Washington |
Ownership | Government - Local |
Emergency Services | Yes |
Medicare ID (CCN) | 500072 |
NPI Number | 1306845557 |
Organization Name | CLALLAM COUNTY PUBLIC HOSPITAL DISTRICT 2 |
Doing Business As | OLYMPIC MEDICAL CENTER |
Address | 939 Caroline St, Port Angeles, WA 98362 |
Hospital Type | General Acute Care Hospital |
Phone Number | 360-417-7000 |
News Archive
The development of blood from stem cell to fully formed blood cell follows a genetically determined program. When it works properly, blood formation stops when it reaches maturity. But when it doesn't, genetic mutations can prevent the stop signal and cause the developing cells to turn cancerous. In research published in Nature, Rockefeller University scientists show for the first time that a misreading of the blood cells' histone code is responsible for acute myeloid leukemia, a rare form of the deadly blood cancer.
Proposals to raise the eligibility age continue to get traction in the fiscal negotiations between the White House and Congress. But liberal Democrats oppose it and express concern that President Barack Obama has not ruled out.
Nanotechnology researchers have known for years that RNA, the cousin of DNA, is a promising tool for nanotherapy, in which therapeutic agents can be delivered inside the body via nanoparticles. But the difficulties of producing long-lasting, therapeutic RNA that remains stable and non-toxic while entering targeted cells have posed challenges for their progress.
Amira Pharmaceuticals, Inc. announced today that it will present preclinical and clinical data from its DP2 receptor antagonist program on December 17, 2010, at Pacifichem 2010 in Honolulu, Hawaii. The data from Amira's clinical-stage DP2 program will be delivered by Brian Stearns, Ph.D., in a presentation titled "Discovery and optimization of a novel series of DP2 antagonists with efficacy in mouse models of COPD and asthma."
› Verified 4 days ago
Able to receive lab results electronically | Yes |
Able to track patients' lab results, tests, and referrals electronically between visits | Yes |
News Archive
The development of blood from stem cell to fully formed blood cell follows a genetically determined program. When it works properly, blood formation stops when it reaches maturity. But when it doesn't, genetic mutations can prevent the stop signal and cause the developing cells to turn cancerous. In research published in Nature, Rockefeller University scientists show for the first time that a misreading of the blood cells' histone code is responsible for acute myeloid leukemia, a rare form of the deadly blood cancer.
Proposals to raise the eligibility age continue to get traction in the fiscal negotiations between the White House and Congress. But liberal Democrats oppose it and express concern that President Barack Obama has not ruled out.
Nanotechnology researchers have known for years that RNA, the cousin of DNA, is a promising tool for nanotherapy, in which therapeutic agents can be delivered inside the body via nanoparticles. But the difficulties of producing long-lasting, therapeutic RNA that remains stable and non-toxic while entering targeted cells have posed challenges for their progress.
Amira Pharmaceuticals, Inc. announced today that it will present preclinical and clinical data from its DP2 receptor antagonist program on December 17, 2010, at Pacifichem 2010 in Honolulu, Hawaii. The data from Amira's clinical-stage DP2 program will be delivered by Brian Stearns, Ph.D., in a presentation titled "Discovery and optimization of a novel series of DP2 antagonists with efficacy in mouse models of COPD and asthma."
› Verified 4 days ago
Olympic Medical Center Acute Care Hospital Location: 939 Caroline St, Port Angeles, Washington 98362 Phone: (360) 417-7000 |